News : Towards providing drugs for Coronavirus patients in India, CSIR has identified the top 25 drugs/drug candidates for repurposing.
- Among these top 25 drugs, Favipiravir a broad spectrum inhibitor of viral RNA polymerase has emerged as of one of the most promising drugs.
- Favipiravir was developed by Fujifilm Toyama Chemical Ltd., and is an approved treatment for common influenza and is marketed in Russia, China and Japan.
- CSIR-IICT, based in Hyderabad has developed a convenient and cost effective synthetic process for Favipiravir.
- Favipiravir is a generic drug and already being used for treatment of influenza and also is in clinical trials for Covid-19 in many countries such as in China, Japan and Italy.